



HR0729

LRB100 15563 MST 30643 r

1

HOUSE RESOLUTION

2 WHEREAS, Fibromuscular dysplasia (FMD) is a disease that
3 causes abnormal cell growth of the arterial wall; it can lead
4 to areas of narrowing, beading, aneurysms, and dissections of
5 the arterial wall; and

6 WHEREAS, Until recently, there has been very little
7 progress in understanding the disease since it was first
8 diagnosed in 1938; there is no known cause or cure for the
9 disease and there are no set protocols to treat the disease;
10 and

11 WHEREAS, FMD has always been considered and is still
12 classified as a rare disease; many researchers now believe FMD
13 is an under-diagnosed disease; some of the data suggest that
14 4-5% of the population may be affected by the disease; and

15 WHEREAS, Ninety percent of the patients affected by FMD are
16 women, but men and children are also afflicted; there are
17 different classifications of FMD; the two most common types are
18 medial fibroplasia and intimal fibroplasia; unlike the adult
19 population, children tend to be diagnosed with intimal
20 fibroplasia, which can be more aggressive; some patients
21 present with both types of the disease; there is no
22 understanding of why there are differences; and

1 WHEREAS, Individuals and families affected by
2 fibromuscular dysplasia often experience problems such as a
3 sense of isolation, and difficulty in obtaining an accurate and
4 timely diagnosis and optimal treatment options; and

5 WHEREAS, The Fibromuscular Dysplasia Society of America
6 (FMDSA) was founded in March of 2003; over the past 14 years,
7 this association has been active and successful with many
8 programs, including public and physician awareness, patient
9 support, and engaging with researchers from around the world;
10 and

11 WHEREAS, The FMDSA is funding the United States Registry
12 for Fibromuscular Dysplasia; previously it was thought that 75%
13 of FMD cases affected the renal arteries, but recent data has
14 proven that to be inaccurate; it is also very common to have a
15 5-year delay from onset of symptoms to diagnosis; and

16 WHEREAS, There is still much needed awareness and research
17 of the disease; FMD patients present with many of the same
18 complaints as other patients with more common conditions, such
19 as hypertension, headaches, and dizziness; others present with
20 TIA or stroke, dissection of an artery, aneurysm, swooshing
21 noise in the ear, and renal infarction; children can present
22 with basic symptoms such as high blood pressure, headaches,

1 insomnia, fatigue, and abdominal pain; misdiagnoses of FMD can
2 lead to severe consequences and disability; and

3 WHEREAS, During the month of March each year, the FMDSA
4 organizes a global observance of the issues associated with
5 fibromuscular dysplasia; patients, medical professionals, and
6 researchers join together to focus attention on fibromuscular
7 dysplasia as a public health issue; therefore, be it

8 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
9 HUNDREDTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we
10 designate March of 2018 as "Fibromuscular Dysplasia Awareness
11 Month" in the State of Illinois; and be it further

12 RESOLVED, That a suitable copy of this resolution be
13 presented to the Fibromuscular Dysplasia Society of America as
14 an expression of our esteem and respect.